Telix Pharmaceuticals Ltd (ASX: TLX) saw its stock soaring 6.39% in Tuesday's intraday trading, following a positive assessment from Bell Potter. The broker has identified Telix as one of four quality stocks now trading at a discount, potentially creating an attractive buying opportunity for investors.

Bell Potter's analysis highlights Telix's impressive performance, noting a 44% EPS CAGR over the last two years. The company's recent strategic moves, including new product launches and acquisitions, have positioned it for continued strong earnings growth in the coming years. Despite this positive outlook, Telix's forward P/E ratio has dropped below 40x, which Bell Potter considers a reasonable valuation given the company's growth prospects.

The market's enthusiastic response to Bell Potter's report suggests that investors are reevaluating Telix's potential in light of its recent achievements and future growth expectations. As a specialist radiopharmaceutical company, Telix stands to benefit from expanded distribution and aggressive investment in its product pipeline, factors that could drive further share price appreciation in the medium to long term.